BBC - Virtus LifeSci Biotech Clinical Trials ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
27.75
-0.22 (-0.78%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous Close27.97
Open27.94
Bid0.00 x 1200
Ask32.00 x 4000
Day's Range27.75 - 28.16
52 Week Range20.22 - 35.86
Volume3,579
Avg. Volume8,266
Net Assets28.51M
NAV27.98
PE Ratio (TTM)N/A
Yield0.00%
YTD Return19.65%
Beta (3Y Monthly)1.87
Expense Ratio (net)0.79%
Inception Date2014-12-16
Trade prices are not sourced from all markets
  • Trump Proposes 2020 Budget: ETFs to Top & Flop
    Zackslast month

    Trump Proposes 2020 Budget: ETFs to Top & Flop

    Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.

  • 6 Wining ETF Areas From a Late Santa Rally
    Zacks4 months ago

    6 Wining ETF Areas From a Late Santa Rally

    These sector ETFs have made the most of the start of this Santa Rally.

  • 4 Worst ETF Areas of Q4
    Zacks4 months ago

    4 Worst ETF Areas of Q4

    These ETF areas have been particularly painful in the bloodbath of the fourth quarter.

  • Healthcare ETFs Sink on JNJ News, ACA Ruling: What???s Ahead?
    Zacks4 months ago

    Healthcare ETFs Sink on JNJ News, ACA Ruling: What???s Ahead?

    Healthcare took a hit recently on Johnson & Johnson news and a federal judge ruling. The rough trading also spread into the ETF world.

  • Top and Flop ETFs at Half-Way Q4
    Zacks5 months ago

    Top and Flop ETFs at Half-Way Q4

    We have highlighted both the best and worst performing zones and their ETFs at halfway Q4.

  • Investopedia6 months ago

    An ETF That Aims to Capitalize on Upcoming Drug Breakthroughs

    In the biotechnology and pharmaceuticals industries, pride of place can be a crucial factor in a company's success. Companies race to develop products and new drugs in the hopes that they will advance through multiple phases of testing by the U.S. Food and Drug Administration (FDA). Although it's rare for a new drug to officially receive approval, when this happens, it is a tremendous boon for the developing company.

  • Scared of a September Lull? Play 6 ETFs
    Zacks8 months ago

    Scared of a September Lull? Play 6 ETFs

    These ETFs may perform well in ill-famed September due to solid fundamentals.

  • 5 Safe and Sound ETF Strategies for 2H
    InvestorPlace9 months ago

    5 Safe and Sound ETF Strategies for 2H

    After a bumpy ride in the first half of the year, global stocks are bouncing back, with iShares MSCI ACWI Index Fund (NASDAQ:ACWI), which targets the global stock market, up 1% last week. The U.S. stocks, as indicated by SPDR S&P 500 ETF (NYSEARCA:SPY), which tracks the S&P 500 index, is up 1.5% to start the second half versus 0.6% gain for Vanguard FTSE All-World ex-US ETF (NYSEARCA:VEU), which targets the international equity market excluding the United States.Source: Investment Zen via Flickr (Modified)

  • 5 ETFs to Play in July
    InvestorPlace10 months ago

    5 ETFs to Play in July

    As promised, President Donald Trump confirmed that he will fire the first shot in the trade war against China by levying tariffs on $34 billion of Chinese imports starting today, triggering almost sure-shot chances of retaliations. Not only China, the European Union is also prepared to cap its imports of steel as part of a knock-on effect of Trump’s protectionism.Source: A Closer Listen

  • 5 Ultra Cheap PEG Stocks Value Investors Will Love
    InvestorPlace11 months ago

    5 Ultra Cheap PEG Stocks Value Investors Will Love

    Value investing is gaining popularity by the day. Buffett believes that proper understanding of the “intrinsic value” of a stock makes the task easier. Yardsticks such as dividend yield, the ratio of price to earnings or to book value are the most common forms of intrinsic value calculation, which can easily single out stocks that the market is currently undervaluing.